6月24日，Twist Bioscience盘中上涨5.2%，报89.35美元/股，成交额1825.99万美元，回补此前因稀释担忧造成的跌幅。
消息面上，Canaccord Genuity近日给予Twist Bioscience买入评级，目标价90美元，显著高于市场共识目标价73.12美元。此前公司于上周向美国证券交易委员会提交货架注册声明，包括一项至多2亿美元普通股的市价发行计划，一度引发稀释担忧导致股价回调。随着市场消化上述信息，投行高目标价对股价形成支撑，股价快速修复至接近90美元目标位。
Twist Bioscience是一家合成生物学平台公司，开发基于硅芯片的DNA合成技术，将专有软件与可伸缩商业基础设施相结合，服务于医疗健康、食品农业、工业化学品及数据存储等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.